טוען...
Overexpression of sortilin is associated with 5‐FU resistance and poor prognosis in colorectal cancer
Colorectal cancer (CRC) is the third most common cancer worldwide. Even if 5‐fluorouracil (5‐FU) is used as the first‐line chemotherapeutic drug, responsiveness is only 20‐30%. Acquired resistance to 5‐FU contributes to both poor patient prognosis and relapse, emphasizing the need to identify biomar...
שמור ב:
| הוצא לאור ב: | J Cell Mol Med |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7810928/ https://ncbi.nlm.nih.gov/pubmed/33325631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.15752 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|